Table 2. Characteristics according to type of admission to the ICU in patients with lung cancer.
Characteristic | Total ICU | Surgical ICU | Medical ICU | P value | ||
---|---|---|---|---|---|---|
(N=23,365) | (N=9,482) | (N=13,883) | ||||
Female | 6,586 (28.2%) | 2,886 (30.4%) | 3,700 (26.7%) | <0.01 | ||
Age | 66.5±10.9 | 63.6±10.1 | 68.5±11.0 | <0.01 | ||
Type of received therapy | ||||||
Surgery only | 4,410 (18.9%) | 3,948 (41.6%) | 462 (3.3%) | <0.01 | ||
Systemic therapy with surgery | 6,343 (27.1%) | 5,534 (58.4%) | 809 (5.8%) | <0.01 | ||
Systemic therapy without surgery | 7,127 (30.5%) | 0 (0.0%) | 7,127 (51.3%) | <0.01 | ||
No treatment | 1,842 (7.9%) | 0 (0.0%) | 1,842 (13.3%) | <0.01 | ||
Refusal of any treatments | 3,643 (15.6%) | 0 (0.0%) | 3,643 (26.2%) | <0.01 | ||
Charlson Comorbidity Index | 9.1±3.9 | 8.6±4.0 | 9.5±3.8 | <0.01 | ||
Overall follow-up (days) | 1,131.3±994.1 | 1,776.3±874.8 | 690.7±813.9 | <0.01 | ||
Renal replacement Therapy | 1,086 (4.6%) | 280 (3.0%) | 806 (5.8%) | <0.01 | ||
Need for Mechanical ventilator | 9,169 (39.2%) | 2,535 (26.7%) | 6,634 (47.8%) | <0.01 | ||
Interval from diagnosis to ICU | 242.9±461.9 | 53.1±197.3 | 372.5±539.5 | <0.01 | ||
ICU mortality at 28-day | 5,692 (24.4%) | 141 (1.5%) | 5,551 (40.0%) | <0.01 | ||
ICU mortality at 60-day | 7,901 (33.8%) | 306 (3.2%) | 7,595 (54.7%) | <0.01 | ||
ICU mortality at 1-year | 11,656 (49.9%) | 1,078 (11.4%) | 10,578 (76.2%) | <0.01 | ||
ICU mortality at 2-year | 13,322 (57.0%) | 1,905 (20.1%) | 11,417 (82.2%) | <0.01 | ||
ICU mortality at 3-year | 14,357 (61.4%) | 2,579 (27.2%) | 11,778 (84.8%) | <0.01 | ||
Overall mortality | 16,429 (70.3%) | 4,226 (44.6%) | 12,203 (87.9%) | <0.01 | ||
Overall ICU mortality | 6,868 (29.4%) | 279 (2.9%) | 6,589 (47.5%) | <0.01 | ||
CPR at death | 2,047 (87.8%) | 474 (93.3%) | 1,573 (86.3%) | <0.01 | ||
ICU length of stay | 34.2±143.9 | 25.1±123.3 | 40.4±156.2 | <0.01 | ||
Survival after ICU discharge | 328.5±547.4 | 908.7±676.2 | 127.5±296.9 | <0.01 |
CPR, cardiopulmonary resuscitation.